In ongoing clinical trials, the safety and efficacy of a human IL-2 mutein Fc fusion protein (Efavaleukin Alfa) to selectively stimulate Tregs is being evaluated in patients with GvHD (NCT03422627) and systemic lupus erythematosus (NCT03451422). Here, IL2 is linked to graft versus host disease.